KBY Biotech Indexv0.0.34
Search
← Pipeline|ZEA-9089

ZEA-9089

Phase 2/3
By Zealand Pharma
Source: Trial-derived·Trials: 2
Modality
Gene Editing
MOA
MDM2i
Target
Menin
Pathway
Angiogenesis
Melanoma
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Jun 2030
Phase 2Current
NCT05498109
1,028 pts·Melanoma
2021-01→TBD·Completed
NCT07932939
1,058 pts·Melanoma
2022-01→2030-06·Recruiting
2,086 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-134.2y awayPh3 Readout· Melanoma
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-06-13 · 4.2y away
Melanoma
RecruitingCompleted|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT05498109Phase 2/3MelanomaCompleted1028EDSS
NCT07932939Phase 2/3MelanomaRecruiting1058ORR
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-8369Eli LillyApprovedMeninAnti-Aβ
DoxacapivasertibEli LillyPhase 3APOC3MDM2i
NVS-1475NovartisPhase 2MeninCD47i
BMY-8678Bristol-Myers SquibbApprovedRETMDM2i
AMG-415AmgenPhase 1CDK2MDM2i
GIL-2037Gilead SciencesApprovedKRASG12DMDM2i
VRT-9481Vertex PharmaPhase 1/2MeninJAK1/2i
OlpainavolisibModernaPhase 1MeninTYK2i
CapiglumideBioNTechPreclinicalCGRPMDM2i
RimasertibExelixisPhase 3B7-H3MDM2i